Major vitamin suppliers are reducing or halting offerings as prices hit unsustainable lows, especially for vitamins A and E. While some buyers are now looking to secure contracts for 2026, most markets remain subdued, and Q4 and Q1 contracts are largely in place. Despite low prices, suppliers are resisting further reductions to maintain stability.
In partnership with Feed Additive Prices
Vitamin E 50%
Most suppliers have significantly reduced their offerings or have even stopped offering altogether. Price levels have dipped too low for sustainability, prompting them to apply the brakes more firmly. Vitamin E prices have declined, reaching levels that, while not historically low, are approaching very low territory. As a result, some buyers are now actively seeking to finalize contracts for Q1 2026.
Vitamin A 1000
Similar to vitamin E, several suppliers have now stopped offering in an attempt to stop the constant price decline. Vitamin A 1000 prices have become historically low. There were already contracts in place for Q4 and Q1, but currently, buyers have returned to the market to secure more material/gaps for Q1. Q4 is mostly contracted already, and some of Q1 was as well some time ago.
Vitamin D3 500
More lower-priced material is now seen in the market as supply is improving compared to earlier this year. This did not trigger a lot of new sales yet for Q1, buyers remain mostly on the sidelines as price levels are still relatively high. Also, Q4 is not fully contracted yet in some areas.
Vitamin B2 80%
FOB China prices are stable to slightly weak. Prices in Europe are stable to weak as well, as Chinese origin is offered more widely now at discounted prices compared to the local Western sources. Prices in the USA are stable. Q4 is mostly contracted by now.
D-Calpan
The market remains stable to weak despite the already low prices, as buyers continue to exercise caution with less demand than usual, while sellers are eager to secure or maintain their market share. Current price levels are said to be unsustainable in the long term, leading suppliers to refrain from further reductions as much as possible. Q4 contracts have not been fully finalized.
Vitamin B3
Prices have stabilised after a period of decline, with some minor increases noted, although they are not substantial. The oversupply situation persists, yet leading suppliers are refraining from further price reductions, citing the unsustainability of such actions. Consequently, prices remain steady to slightly firm, albeit at a low level. The contracts for Q4 and a significant portion of Q1 are already secured.
Biotin
Static market and despite the super low prices and unsatisfying business for manufacturers, maintaining market share seems to prevail for them. Q4 is contracted, and a portion of Q1 is as well.
Vitamin C 35% mono
The decline in prices has been halted for several weeks, and a modest increase has even been observed. Manufacturers have been resolutely opposing any further drop in prices, and thus far, their efforts appear to be effective. Q4 contracts are in place, and a significant portion of Q1 is also secured.
